Evidence-based deprescribing: Reversing the tide of potentially inappropriate polypharmacy

Journal of Clinical Outcomes Management

Volumn 23, Issue 8, 2016, Pages 359-369

  Scott, Ian A ^a,b   Anderson, Kristen ^b   Freeman, Christopher ^c  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c Charming Institute   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AWARENESS; CLINICAL PRACTICE; CLINICAL PROTOCOL; COMPETENCE; DEATH; DISABILITY; EVIDENCE BASED MEDICINE; HOSPITALIZATION; HUMAN; OUTCOME ASSESSMENT; PATIENT CARE; POLYPHARMACY; POTENTIALLY INAPPROPRIATE MEDICATION; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SELF CONCEPT;

EID: 84984685550     PISSN: 10796533     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Qato DM, Alexander GC, Conti RM, et . Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 2008;300:2867-78.
2. Kantor ED, Rehm CD, Haas JS, et al. Trends in prescription drug use among adults in the United States from 1999-2012. JAMA 2015;314:1818-31.
3. Wise J. Polypharmacy: a necessary evil. BMJ 2013;347: f7033.
4. Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol 2012;65:989-95.
5. Atkin PA, Veitch PC, Veitch EM, Ogle SJ. The epidemiology of serious adverse drug reactions among the elderly. Medicines Aging 1999;14:141-52.
6. Roughead EE, Anderson B, Gilbert AL. Potentially inappropriate prescribing among Australian veterans and war widows/widowers. Intern Med J 2007;37:402-5.
7. Stafford AC, Alswayan MS, Tenni PC. Inappropriate prescribing in older residents of Australian care homes. Clin Pharmacol Therapeut 2011;36:33-44.
8. Tjia J, Briesacher BA, Peterson D, et al. Use of medications of questionable benefit in advanced dementia. JAMA Intern Med 2014;174:1763-71.
9. Tjia J, Velten SJ, Parsons C, et al. Studies to reduce unnecessary medication use in frail older adults: A systematic review. Drugs Aging 2013;30:285-307.
10. Anathhanam AS, Powis RA, Cracknell AL, Robson J. Impact of prescribed medicines on patient safety in older people. Ther Adv Drug Saf 2012;3:165-74.
11. Opondo D, Eslami S, Visscher S, et al. Inappropriateness of medication prescriptions to elderly patients in the primary care setting: a systematic review. PLoS One 2012;7(8):e43617.
12. Kalisch LM, Caughey GE, Barratt JD, et al. Prevalence of preventable medication-related hospitalizations in Australia: an opportunity to reduce harm. Int J Qual Health Care 2012;24:239-49.
13. Bero LA, Lipton HL, Bird JA. Characterisation of geriatric drug-related hospital readmissions. Med Care 1991;29:989-1003.
14. Jyrkkä J, Enlund H, Korhonen MJ, et al. Polypharmacy status as an indicator of mortality in an elderly population. Drugs Aging 2009;26:1039-48.
15. Steinman MA, Miao Y, Boscardin WJ, et al. Prescribing quality in older veterans: a multifocal approach. J Gen Intern Med 2014;29:1379-86.
16. Goldberg R, Mabee J, Chan L, Wong S. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med 1996;14:447-50.
17. Elliott RA, Booth JC. Problems with medicine use in older Australians: a review of recent literature. J Pharm Pract Res 2014;44:258-71.
18. Barat I, Andreasen F, Damsgaard EM. Drug therapy in the elderly: what doctors believe and patients actually do. Br J Clin Pharmacol 2001;51:615-22.
19. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005;165:1147-52.
20. Gnjidic D, Hilmer SN. Emergency hospitalizations for adverse drug events. N Engl J Med 2012;366:859.
21. Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Waite L, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol 2012;65:989-95.
22. Cherubini A, Oristrell J, Pla X, et al. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med 2011;171:550-6.
23. Bugeja G, Kumar A, Banerjee AK. Exclusion of elderly people from clinical research: a descriptive study of published reports. BMJ 1997;315:1059.
24. Mangin D, Heath I, Jamoulle M. Beyond diagnosis: rising to the multimorbidity challenge. BMJ 2012;344:e3526.
25. Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005;294:716-24.
26. McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004;56:163-84.
27. Hilmer SN, Mager DE, Simonsick EM, et al. Drug Burden Index score and functional decline in older people. Am J Med 2009;122:1142-9.
28. Reeve E, Gnjidic D, Long J, Hilmer S. A systematic review of the emerging definition of 'deprescribing' with network analysis: implications for future research and clinical practice. Br J Clin Pharmacol 2015;80:1254-68.
29. Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy - the process of deprescribing. JAMA Intern Med 2015;175:827-34.
30. Scott IA, Gray LA, Martin JH, et al. Deciding when to stop: towards evidence-based deprescribing of drugs in older populations. Evidence-based Med 2013;18:121-4.
31. Reeve E, Shakib S, Hendrix I, et al. Review of deprescribing processes and development of an evidence-based, patient-centred deprescribing process. Br J Clin Pharmacol 2014;78:738-47.
32. Alldred D. Deprescribing: a brave new word? Int J Pharm Pract. 2014;22:2-3.
33. Kaur S, Mitchell G, Vitetta L, Roberts MS. Interventions that can reduce inappropriate prescribing in the elderly: a systematic review. Drugs Aging 2009;26:1013-28.
34. Tjia J, Velten SJ, Parsons C, et al. Studies to reduce unnecessary medication use in frail older adults: A systematic review. Drugs Aging 2013;30:285-307.
35. Thomas R, Huntley AL, Mann M, et al. Pharmacist-led interventions to reduce unplanned admissions for older people: a systematic review and meta-analysis of randomised controlled trials. Age Ageing 2014;43:174-87.
36. Gnjidic D, Le Couteur DG, Kouladjian L, Hilmer SN. Deprescribing trials: Methods to reduce polypharmacy and the impact on prescribing and clinical outcomes. Clin Geriatr Med 2012;28:237-53.
37. Patterson SM, Hughes C, Kerse N, et al. Interventions to improve use of polypharmacy for older people. Cochrane Database Syst Rev 2012;5:CD008165.
38. Chhina HK, Bhole VM, Goldsmith C, et al. Effectiveness of academic detailing to optimize medication prescribing behaviour of family physicians. J Pharm Pharm Sci 2013;16:511-29.
39. Alldred DP, Raynor DK, Hughes C, et al. Interventions to optimise prescribing for older people in care homes. Cochrane Database Syst Rev 2013;CD009095.
40. García-Gollarte F, Baleriola-Júlvez J, Ferrero-López I, et al. An educational intervention on drug use in nursing homes improves health outcomes and resource utilization and reduces inappropriate drug prescription. J Am Dir Assoc 2014;15:885-91.
41. Pitkälä KH, Juola A-L, Kautiainen H, Soini H, et al. Education to reduce potentially harmful medication use among residents of assisted living facilities: A randomized controlled trial. J Am Dir Assoc 2014;15:892-8.
42. Tannenbaum C, Martin P, Tamblyn R, et al. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education. The EMPOWER cluster randomized trial. JAMA Intern Med 2014;174:890-8.
43. Iyer S, Naganathan V, McLachlan AJ, Le Couteur DG. Medication withdrawal trials in people aged 65 years and older: a systematic review. Drugs Aging 2008;25:1021-31.
44. Declercq T, Petrovic M, Azermai M, et al. Withdrawal versus continuation of chronic antipsychotic medicines for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev 2013;3:CD007726.
45. Ekbom T, Lindholm LH, Odén A, et al. A 5-year prospective, observational study of the withdrawal of antihypertensive treatment in elderly people. J Intern Med 1994;235:581-588.
46. Kutner JS, Blatchford PJ, Taylor DH Jr, et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. JAMA Intern Med 2015;175:691-700.
47. Page AT, Clifford RM, Potter K, Schwartz D, Etherton-Beer CD. The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. Br J Clin Pharmacol 2016 Apr 14. [Epub ahead of print]
48. Garfinkel D, Zur-Gil S, Ben-Israel J. The war against polypharmacy: a new cost-effective geriatric-palliative approach for improving drug therapy in disabled elderly people. Isr Med Assoc J 2007;9:430-4.
49. Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medicines in older adults: addressing polypharmacy. Arch Intern Med 2010;170:1648-54.
50. McKean M, Pillans P, Scott IA. A medication review and deprescribing method for hospitalised older patients receiving multiple medications. Intern Med J 2016;46:35-42.
51. Mudge A, Radnedge K, Kasper K, et al. Effects of a pilot multidisciplinary clinic for frequent attending elderly patients on deprescribing. Aust Health Rev 2015; Jul 6. [Epub ahead of print]
52. Gallagher PF, O'Connor MN, O'Mahony D. Prevention of potentially inappropriate prescribing for elderly Patients: A randomized controlled trial using STOPP/START criteria. Clin Pharmacol Therap 2011;89:845-54.
53. Dalleur O, Boland B, Losseau C, et al. Reduction of potentially inappropriate medications using the STOPP criteria in frail older inpatients: a randomised controlled study. Drugs Aging 2014;31:291-8.
54. Potter K, Flicker L, Page A, Etherton-Beer C. Deprescribing in frail older people: A randomised controlled trial. PLoS One 2016;11(3):e0149984.
55. Conklin J, Farrell B, Ward N, et al. Developmental evaluation as a strategy to enhance the uptake and use of deprescribing guidelines: protocol for a multiple case study. Implement Sci 2015;10:91-101.
56. Lindsay J, Dooley M, Martin J, et al. The development and evaluation of an oncological palliative care deprescribing guideline: the 'OncPal deprescribing guideline' Support Care Cancer 2015;23:71-8.
57. Miller GC, Valenti L, Britt H, Bayram C. Drugs causing adverse events in patients aged 45 or older: a randomised survey of Australian general practice patients. BMJ Open 2013;3:e003701.
58. Budnitz DS, Lovegrove MC, Shebab N, Richards CL. Emergency hospitalisations for adverse drug events in older Americans. N Engl J Med 2011;365:2002-12.
59. Scott IA, Andersen K, Freeman C. Review of structured guides for deprescribing. Eur J Hosp Pharm 2016. In press.
60. Scott IA, Le Couteur D. Physicians need to take the lead in deprescribing. Intern Med J 2015;45:352-6.
61. Poudel A, Ballokova A, Hubbard RE, et al. An algorithm of medication review in residential aged care facilities: focus on minimizing use of high risk medications. Geriatr Gerontol Int Sep 3. [Epub ahead of print]
62. Scott IA, Martin JH, Gray LA, Mitchell CA. Effects of a drug minimisation guide on prescribing intentions in elderly persons with polypharmacy. Drugs Ageing 2012;29:659-67.
63. Bennett A, Gnjidic D, Gillett M, et al. Prevalence and impact of fall-risk-increasing drugs, polypharmacy, and drug-drug interactions in robust versus frail hospitalised falls patients: a prospective cohort study. Drugs Aging 2014;31:225-32.
64. Black DM, Schwartz AV, Ensrud KE, et al. FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomised trial. JAMA 2006;296:2927-38.
65. Sever PS, Chang CL, Gupta AK, et al. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid lowering arm in the UK. Eur Heart J 2011;32:2525-32.
66. Anderson K, Stowasser D, Freeman C, Scott I. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open 2014;4.
67. Reeve E, To J, Hendrix I, et al. Patient barriers to and enablers of deprescribing: a systematic review. Drugs Aging 2013;30:793-807.
68. Palagyi A, Keay L, Harper J, et al. Barricades and brickwalls - a qualitative study exploring perceptions of medication use and deprescribing in long-term care. BMC Geriatr 2016;16:15.
69. Garfinkel D, Ilhan B, Bahat G. Routine deprescribing of chronic medications to combat polypharmacy. Ther Adv Drug Saf 2015;6:212-33.
70. Reeve E, Shakib S, Hendrix I, et al. The benefits and harms of deprescribing. Med J Aust 2014;201:386-9.
71. Betteridge TM, Frampton CM, Jardine DL. Polypharmacy - we make it worse! A cross-sectional study from an acute admissions unit. Intern Med J 2012;42:208-11.
72. Hubbard RE, Peel NM, Scott IA, et al. Polypharmacy among inpatients aged 70 years or older in Australia. Med J Aust 2015;202:373-7.
73. Klopotowska JE, Wierenga PC, Smorenburg SM, et al. Recognition of adverse drug events in older hospitalized medical patients. Eur J Clin Pharmacol 2013;69:75-85.
74. Reeve E, Wiese MD, Hendrix I, et al. People's attitudes, beliefs, and experiences regarding polypharmacy and willingness to deprescribe. J Am Geriatr Soc 2013;61:1508-14.
75. Kalogianis MJ, Wimmer BC, Turner JP, et al. Are residents of aged care facilities willing to have their medications deprescribed? Res Social Adm Pharm 2015. Published online 18 Dec 2015.
76. Turner JP, Edwards S, Stanners M, et al. What factors are important for deprescribing in Australian long-term care facilities? Perspectives of residents and health professionals. BMJ Open 2016;6:e009781.
77. Page AT, Etherton-Beer CD, Clifford RM, et al. Deprescribing in frail older people - Do doctors and pharmacists agree? Res Social Adm Pharm 2015;12:438-49.
78. Luymes CH, van der Kleij RM, Poortvliet RK, et al. Deprescribing potentially inappropriate preventive cardiovascular medication: Barriers and enablers for patients and general practitioners. Ann Pharmacother 2016 Mar 3. [Epub ahead of print]
79. Hoffmann TC, Del Mar C. Patients' expectations of the benefits and harms of treatments, screening, and tests: a systematic review. JAMA Intern Med 2015;175:274-86.
80. Martin P, Tamblyn R, Ahmed S, Tannenbaum C. A drug education tool developed for older adults changes knowledge, beliefs and risk perceptions about inappropriate benzodiazepine prescriptions in the elderly. Patient Educ Couns 2013;92:81-7.
81. Hamilton H, Gallagher P, Ryan C, et al. Potentially inappropriate medicines defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. Arch Intern Med 2011;171:1013-7.
82. NHS Highland. Polypharmacy: guidance for prescribing in frail adults. Accessed at: www.nhshighland.scot.nhs.uk/publications/documents/guidelines/polypharmacyguidanceforprescribinginfrailadults.pdf.
83. Anderson K, Foster MM, Freeman CR, Scott IA. A multifaceted intervention to reduce inappropriate polypharmacy in primary care: research co-creation opportunities in a pilot study. Med J Aust 2016;204:S41-4.
84. A practical guide to stopping medicines in older people. Accessed at: www.bpac.org.nz/magazine/2010/april/stopGuide.asp.
85. www.cpsedu.com.au/posts/view/46/Deprescribing-Documents-now-Available-for-Download.
86. Bregnhøj L, Thirstrup S, Kristensen MB, et al. Combined intervention programme reduces inappropriate prescribing in elderly patients exposed to polypharmacy in primary care. Eur J Clin Pharmacol 2009;65:199-207.